Nicholas Chiu, MD MPH

Our 🚨NEW PAPER🚨 out in @JACCJournals #JACCAdvances 📌~5.6 million US adults w/ CKD qualify for SGLT-2i 📌~46% eligible for empa had UACR <30 🔑Routine UACR testing may capture at-risk pts Team: @RahulAggarwalMD @LeonardChiuMD @mvaduganathan @gcfmd Thanks⭐️Mentor @DLBHATTMD!

A true pleasure to connect with so many brilliant faculty & fellows @YaleCardiology Grand Rounds We explored the evidence on how sweeping policy reforms over the past 20 years have shaped the #cardiovascular health of millions in the US - and the urgent challenges that lie ahead

Incredibly honored to receive the 2025–2026 Glorney-Raisbeck Junior Faculty Research Award in Cardiovascular Diseases from the New York Academy of Medicine! 🙌🎉 This $85K award supports our work leveraging opportunistic algorithms to improve CV risk prediction & prevention🫀

Shout out to the cardiology fellows @CedarsCards @SmidtHeart who decided to give me a teaching award! I hope to continue to support you all in any way I can.

Celebrating an incredible group of graduating fellows. your dedication, resilience, and heart (in every sense!) have inspired us all. Wishing you continued success and fulfillment in the journeys ahead. Grateful to have shared this chapter with you.💔➡️❤️ #Cardiology #Fellowship

💥 New in Nature Cardiovascular Research! In our EMPACT-MI analysis, empagliflozin: ✅ Stabilized kidney function post-MI ✅ Reduced HF events ✅ Was safe to start early—even with CKD Supports SGLT2i safety post-MI 💊🫀 📖: nature.com/articles/s4416… ⭐️Mentor @DLBHATTMD

Potential impact of the ongoing VICTORION-1 PREVENT trial by @RahulAggarwalMD - bottom line, millions of patients could be eligible for therapy with inclisiran. #Cardiology #Cardiovascular #Prevention #CardioTwitter #CardioX

Always inspiring to hear @MathewMaurer talk about Cardiac Amyloidosis Was so nice to reunite w/ my prior mentor @ColumbiaCardio as he visited @utswheart for his Grand Rounds tour de force! @JoshuaBeckmanMD @GailPetersonMD @MaryjaneFarrMD @josephahill @dramitkhera @AmitGoyalMD

#ACC25 is a wrap! Incredibly proud of all the trainees in the Health Policy Research Section, who presented impactful work focused on the intersection of cardiovascular care & health policy @SmithBIDMC Check out our website: bit.ly/3FQEqvA

Incredibly excited to publish our NOTIFY-LVH randomized trial of 648 patients within the @MassGenBrigham system, highlighting the potential of leveraging preexisting cardiovascular data to improve the detection and treatment of chronic cardiovascular conditions.

That’s a wrap on #ACC25 with this exceptional group of @SmithBIDMC research trainees and @BIDMCVFellows

1/ In @JAMACardio at #ACC25, we find significantly ⬆️rates of CV🫀risk factors + diseases in the 1 in 5 Americans living in rural counties. Rural-urban differences were largest among young adults and almost entirely explained by social risk factors. Link: jamanetwork.com/journals/jamac…

More @SmithBIDMC research focused on changes in cardiometabolic health among US adults post pandemic spearheaded by the amazing Ivy Shi and @RahulAggarwalMD

Terrific presentation by #ACC25 Young Investigator Finalist @LiuMichaelON examining the factors that contribute to rural-urban disparities in #cardiovascular health Simultaneously published @JAMACardio jamanetwork.com/journals/jamac…

Great work in @TheLancetEndo led by @RahulAggarwalMD showing the benefits of #heartattack and #stroke reduction by combining SGLT1 and SGLT2 inhibition with #sotagliflozin. #cardiology #cardiotwitter #cardioX #diabetes #kidneydisease @gabrielsteg @cpcannon

In @AnnalsofIM, we find that patients in Medicare Advantage have a similar burden of many chronic medical conditions as those in Traditional Medicare Yet these private insurance operated Advantage plans cost $83 billion more. Could over coding of diagnoses be causing this?…

In JAHA, our secondary analysis of REDUCE-IT shows that icosapent ethyl reduces cardiovascular events among patients with high CV risk and mild-moderate hypertriglyceridemia, even if they have well-controlled LDL (<55). Article here: ahajournals.org/doi/full/10.11… @DLBHATTMD…

There is a lot of buzz about our new paper in Nature Medicine on the effects of LLMs (GPT-4) on physician management reasoning! I had TONS of fun working on this -- but what it MEANS requires some unpacking. A 🧵⬇️ x.com/EricTopol/stat…

1/Our new paper on the SCORED Trial, now published @TheLancetEndo 🧵 Sotagliflozin, a dual SGLT1/2 inhibitor, improved both myocardial infarction & stroke—a benefit in both not observed with other SGLT inhibitors. authors.elsevier.com/c/1kcMx7tNucqx… Special thanks to ⭐️mentor @DLBHATTMD

Congratulations to our very own second year fellow Dr. Alex Levy on this new editorial discussing the TRILUMINATE 1-year outcomes - all under the guidance of @GreggWStone! Lucky to have such mentorship present here at @MountSinaiHeart. Link here: jacc.org/doi/10.1016/j.…

"Does lowering LDL-C to very low levels result in long-term cognitive impairment?" 🧠🫀 I've heard this question many times. Now we have long-term data. A 🧵 on our new @NEJMEvidence paper: evidence.nejm.org/doi/full/10.10… @TIMIStudyGroup @rgiugliano @DrM_ODonoghue